A012303: ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients with Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy with HER2 Blockade
- Sponsor:
- Alliance for Clinical Trials in Oncology
- Sponsor Study ID:
- A012303
- CTO #:
- 104271
- NCT Number:
- NCT06876714
- Phase:
- III
- Protocol Type:
- Treatment
- Age Group:
- Adults
- Disease Sites:
- Breast
- Study Objectives:
- To evaluate whether 6 months of combined neo/adjuvant HER2 blockade results in a non-inferior recurrence-free survival (RFS) compared to 12 months of combined neo/adjuvent HER2 blockade, in patients with early stage HER2+ breast cancer who achieve pCR after neoadjuvant chemotherapy with HER2 blockade.
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Principal Investigator, Sivapiragasam, Abirami, at sivapira@musc.edu .
- Study Coordinator, Gelardi, Theresa, at gelardi@musc.edu .
Trial opened at the following institutions:
Tidelands Health, Medical University of South Carolina